UNSPSC 51191557: Prorenoate

This classification denotes a potassium-sparing diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WET36J3301. European Medicines Agency schedules Prorenoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10129MIG. Prorenoate generally arises in the molecular formula C23H31O4.K. The term PRORENOATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) As of Q4 2014, PRORENOATE remains the US FDA Preferred Term for this commodity.

Prorenoate bears US NLM identifiers UMLS ID CL412716 and NCI Concept Code C84117. SMILES: CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4CCC5(CCC(=O)O)O)C.

UNSPSC 51191557 Prorenoate is a Commodity code covering chemical supply for municipal water treatment and pharmaceutical distribution to state and local government facilities. The code captures two distinct procurement streams: chemicals like sodium bisulfite for water pollution control operations, and generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to health and human services agencies. State and local buyers under this code include municipal water departments, state health systems, and cooperative purchasing alliances serving multiple state and local agencies. The City of Meriden represents the water-treatment side; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the pharmaceutical and OTC distribution model serving participating state, local, and interstate health facilities.

Recent activity spans Connecticut and Minnesota, with the MMCAP alliance extending coverage to Oregon and other participating jurisdictions. The City of Meriden issued IFB B027-15 for sodium bisulfite chemical supply to its Water Pollution Control Facility with bids due July 29, 2026, requiring General Liability coverage of $1,000,000 to $2,000,000, performance and payment bonds, and firm pricing for the contract period. MMCAP issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with proposals due March 26, 2026, seeking manufacturers to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with awards effective July 1, 2026; evaluation weighted price competitiveness at 75 percent, fixed pricing at 10 percent, and compliance with administrative requirements at 15 percent, with vendors obligated to pay a 3 percent administrative fee and maintain insurance including $5,000,000 commercial general liability per occurrence.